SOURCE: Xtalks

Xtalks Webinars

December 07, 2015 15:00 ET

Top News Stories You Might Have Missed From Xtalks

Xtalks Provides Current Articles Daily in the Life Science Industry

TORONTO, ON--(Marketwired - December 07, 2015) - Check out all news stories here: http://xtalks.com/News.ashx. Subscribe to our weekly newsletter: http://register.xtalks.com/newsblogs.

Evolution Of Gut Bacteria Affected By Host Immune System -- http://ow.ly/VzKgv
(Dec 7) A new study conducted at the Instituto Gulbenkian de Ciência (IGC) in Portugal, suggests that the evolution of beneficial bacteria in the human gut may be influenced by the immune system.

Researchers Deactivate Cancer-Causing Proteins -- http://ow.ly/VzKt9
(Dec 4) After 30 years of study by researchers around the world, a team of scientists at the University of Toronto in Canada, have developed an inhibitor drug for the cancer-causing protein, Ras.

Reversal of Type 2 Diabetes Possible By Removing Excess Fat From Pancreas -- http://ow.ly/VzKFL
(Dec 3) Researchers at Newcastle University in the UK, have shown that fat -- or triglyceride -- accumulation around the pancreas may be the cause of Type 2 diabetes, and losing just one gram of this fat can reverse the disease.

Bristol-Myers' New Cancer Medication Costs Blockbuster $142,000 Per Year -- http://ow.ly/VzL5Z
(Dec 3) The newest multiple myeloma cancer treatment developed by Bristol-Myers Squibb -- Empliciti -- in collaboration with AbbVie, won US Food and Drug Administration (FDA) approval on Monday.

Breast Cancer Gene BRCA1 Implicated In Alzheimer's Disease -- http://ow.ly/VzLhv
(Dec 2) The BRCA1 protein is found in lower than normal levels in the brains of people with Alzheimer's disease, leading the researchers to postulate that a lack of the protein in neurons may lead to abnormal brain function and cognitive impairment indicative of the disease.

Teva and Takeda Partner To Meet Demand For Generics In Japan -- http://ow.ly/VzLl0
(Dec 2) Yesterday, Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited announced their intention to form a partnership, with a focus on providing generics to the Japanese market.

Well-Characterized Enzymes Could Have Potential In Drug Discovery -- http://ow.ly/VzLvY
(Dec 1) A collaboration between the University of Cambridge in the UK and AstraZeneca's R&D unit, MedImmune, has discovered that well-characterized enzymes may have the potential to treat certain diseases, and further the drug discovery process.

FDA Approves First Adjuvant-Containing Influenza Vaccine -- http://ow.ly/VzLAg
(Dec 1) Last week, the US Food and Drug Administration (FDA) approved a seasonal influenza vaccine -- Fluad -- which is the first of its kind to contain an adjuvant.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx.

Contact Information